Tests venetoclax with chemotherapy in relapsed or refractory acute myeloid leukemia
Tests venetoclax plus CACAG chemotherapy against standard care in people with returned leukemia.
Plain-language title generated from the registry record
Registry title: Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 14 to 75 with acute myeloid leukemia that came back or did not respond to treatment, and who have good enough liver and kidney function.
- Age
- 14 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory acute myeloid leukemia (R/R AML), diagnosed by the 2021 CMA criteria. ECOG score 0-3 and expected survival of at least 4 months.
Main reasons for not taking part
- Allergy or contraindication to the study drug
- Pregnant or breast-feeding women
- Known history of alcohol or drug addiction
- Mental illness or other state that prevents following the protocol
- Less than 6 weeks after surgery on an important organ
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 75 years old?
Source: NCT06084819, who can take part
Where in China
- Chinese PLA General HospitalBeijing, ChinaContact: Daihong Liu, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT06084819
- Record updated
- 2 April 2026
- Original description
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.Read full original descriptionShow less
A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.
Inclusion: Patients who are able to understand and willing to sign the informed consent form (ICF); All patients should aged 14 to 75 years,no gender limitation; Patients with R/R AML, diagnosed in accordance with the 2021 edition of the CMA criteria; Liver function: ALT and AST≤2.5 times the upper limit of normal ,bilirubin≤2 times the upper limit of normal; Renal function: creatinine ≤the upper limit of normal; Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness; The score of Eastern Cooperative Oncology Group (ECOG) is 0-3,and the predicted survival ≥ 4 months; Patients without severe allergic constitution.
Exclusion: Less than 6 weeks after surgical operation of important organs; Patients with allergy or contraindication to the study drug; Patients with a known history of alcohol or drug addiction on the basis that there could be a higher risk of non-compliance to study treatment; Patients with mental illness or other states unable to comply with the protocol; Liver function: ALT and AST>2.5 times the upper limit of normal ,bilirubin>2 times the upper limit of normal;Renal function: creatinine >the upper limit of normal; Female patients who are pregnant or breast-feeding; The patient is not suitable for this clinical trial (poor compliance, substance abuse, etc.).